EUROESPES BIOMEDICAL RESEARCH CENTER
Institute of Medical Science and Genomic Medicine

Pharmacogenetics of Alzheimer's Disease
The Critical Role of the APOE-TOMM40 Region

Ramón Cacabelos, M.D., Ph.D., D.M.Sci.

Professor & Chairman of Genomic Medicine
EuroEspes BioMedical Research Center
Institute of Medical Science and Genomic Medicine
15165-Bergondo, Corunna, Spain

/ PERSONALIZED MEDICINE
MEDICINA PERSONALIZADA /

T. (+34) 981 780 505
F. (+34) 981 780 511
info@euroespes.com
www.euroespes.com
Santa Marta de Babío s/n
15165 Bergondo · A Coruña, Spain

Alzheimer's disease











Pathogenic Factors in Complex Disorders



Alzheimer's disease Biomarkers

Genomic Background


Clinical Phenotype



Pathogenic Mechanisms

Neurodegeneration





Genomics – Transcriptomics – Proteomics -- Metabolomics

Major Risk Factors for Dementia

EuroEspes Biomedical Research Center
Institute for CNS Disorders and Genomic Medicine










Genomics



Aging




EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine
Santa Marta de Babío | 15165 Bergondo, Coruña, Spain | Tel.: +34 981 780 505 Fax: +34 981 780 511
rcacabelos@euroespes.com | www.euroespes.com

EuroEspes

Major Risk Factors for Dementia

EuroEspes Biomedical Research Center
Institute for CNS Disorders and Genomic Medicine




Cerebrovascular Disorders

Brain Trauma

EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine
Santa Marta de Babío | 15165 Bergondo, Coruña, Spain | Tel.: +34 981 780 505 Fax: +34 981 780 511
rcacabelos@euroespes.com | www.euroespes.com

EuroEspes

Major Risk Factors for Dementia






Cardiovascular disorders
Hypertension
Atherosclerosis

EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine
Santa Marta de Babío | 15165 Bergondo, Coruña, Spain | Tel.: +34 981 780 505 Fax: +34 981 780 511
rcacabelos@euroespes.com | www.euroespes.com


EuroEspes

Major Risk Factors for Dementia











Lipid Metabolism Alterations (Endogenous + Exogenous)


Alzheimer's Disease






Phenotypic features


Alzheimer's disease Neuropathology










Alzheimer's Disease Microscopic Neuropathology










Alzheimer's Disease




Genomic Factors


Chair of Genomic Medicine
Camilo José Cela University

euroespes
BIOMEDICAL RESEARCH CENTER








Alzheimer's disease-related genes




APP Mutations








Alzheimer's Disease
Healthy Neuron
Amyloid Plaque
Damaged Neuron
Fibril
sAPPβ
sAPPα
Beta-amyloid
Oligomers
Presenilin
Beta-secretase
Alpha-secretase
Presenilin
Tangle
Gamma-secretase Complex
Gamma-secretase Complex
Damaged Mitochondrion
Tau Fragments
Healthy Microtubule
Disintegrating Microtubule
Healthy Mitochondrion





euroespes
MEDICINA PERSONALIZADA


CENTRO DE INVESTIGACIÓN BIOMÉDICA EUROESPES
Instituto de Ciencias Médicas y Medicina Genómica


rcacabelos@euroespes.com
www.euroespes.com

Presenilin-1 (PSEN1) and 2 (PSEN2) Mutations













MAPT Mutations









euroespes
MEDICINA PERSONALIZADA


CENTRO DE INVESTIGACIÓN BIOMÉDICA EUROESPES
Instituto de Ciencias Médicas y Medicina Genómica

rcacabelos@euroespes.com
www.euroespes.com

Pathogenic Genes

Mechanistic Genes

Transporter Genes




Metabolic Genes

Pleiotropic Genes


Pharmacogenomic Outcome

Influence of APOE genotypes on Alzheimer's disease-related phenotypes




APOE Genotype Distribution

APOE Distribution in Hypertension, Diabetes and Dementia



Cacabelos et al., EuroEspes Biomedical Research Center, 2000

APOE Genotypes in CNS Disorders




	C	ANX	DEP	PSY	STR	AD	PAR	ADHD	MIG	EPI	VD	VE	MS	CVI	BT	CNN	MR	PTBS
APOE-4/4	1,59	1,4	0,96	0,62	0	6,06	2,74	0	1,84	0	6,57	2,64	0	2,17	0	0	0,87	1,69
APOE-3/4	18,41	15,09	15,27	20,37	17,91	30,3	17,81	14,29	22,13	23,94	35,85	18,68	14,29	15,94	9,09	24	24,35	16,96
APOE-3/3	71,11	74,74	74,22	63,58	74,63	54,55	65,75	76,19	66,82	66,2	48,99	70,79	61,9	73,19	81,82	68	64,34	67,8
APOE-2/4	1,27	1,05	1,67	1,23	2,98	1,3	1,37	0	1,84	0	1,52	1,58	0	0,73	9,09	0	1,74	0
APOE-2/3	7,3	7,72	7,64	13,58	4,48	7,79	12,33	9,52	6,91	9,86	7,07	6,05	23,81	7,97	0	8	8,7	11,86
APOE-2/2	0,32	0	0,24	0,62	0	0	0	0	0,46	0	0	0,26	0	0	0	0	0	1,89


Cacabelos et al (2010)

Influence of APOE on
Lipid Metabolism
Vascular Disorders
and Atherosclerosis











APOE-Related Cholesterol Levels in Dementia

Plasma Choleserol Levels in Alzheimer's Disease




APOE-Related Triglyceride Levels in Dementia


Plasma Triglyceride Levels in Alzheimer's Disease





Aortic Atherosclerosis

Atheroma Plaque Size in the Abdominal Aorta of Patients with Hypercholesterolemia










APOE-3/3










APOE-3/4


APOE-Related Brain Atrophy (Interventricular Distance)




APOE-Related Interhippocampal Distance











Cacabelos, 2005




Control	GDS-3	GDS-4	GDS-5	GDS-6	GDS-7



APOE-2/2	APOE-2/3	APOE-2/4	APOE-3/3	APOE-3/4	APOE-4/4


R. Cacabelos (2005)

Optical Brain Topography



APOE Genotype-Related
Cortical DOT Hemoglobin Consumption


Brain Amyloidogenesis and Potential Therapeutic Interventions




PS2 1q31-q32	TACE 2p25	CASP3 4q35	CTSB 8p22	A2M 12p13.3-p12.3	UB 17p12-p11.1	NOTCH 19p13.2-p13.1	PEN-2 Chr.19
Nicastrin Chr.1	HSPD1 2q33.1	PARK1 4p21	IDE 10q23-q25	LRP1 12q13.1-q13.3	TAU 17q21.1	APOE 19q13.2	PRNP 20pter-p12
APH-1 Chr.1/5	GACE ???	PSMC2 7q22.1-q22.3	BACE 11q23.3	PS1 14q24.3	ACE 17q23	PSMC1 19p13.3	APP 21q21


R. Cacabelos. Pharmacogenomics 2004; 5(8):1049-1105

APOE-APOB-APOC3-CETP-LPL HAPLOTYPES





APOE-Related Cholesterol Levels in Alzheimer's Disease






APOE-Related Cholesterol Levels in Alzheimer's disease









Sex-Related Cholesterol Response to Atorvastatin + LipoEsar

Hypercholesterolemia in Alzheimer's disease




APOE-Related Cholesterol Response to Hypolipemic Treatment


Alzheimer's Disease




APOE-Related Cholesterol Response to Atorvastatin + LipoEsar in patients with Alzheimer's disease



Tetragenic (CYP2D6-CYP2C19-CYP2C9-CYP3A4/5) Haplotypes




CYP Haplotype-Related Blood Total Cholesterol Levels




Frequent CYP Haplotypes (>1%) in the Spanish population

Haplotype	Genotype	Frequency (%)
H17	1/1-1/17-1/1-3/3	1,1
H73	1/4-1/2-1/2-3/3	1,1
H127	4/4-1/1-1/1-3/3	1,1
H54	1/4-1/1-1/1-1/3	1,27
H25	1/1-1/2-1/1-1/3	1,66
H6	1/1-1/1-1/2-1/3	1,78
H59	1/4-1/1-1/3-3/3	1,83
H27	1/1-1/2-1/2-3/3	1,87
H38	1xN/1-1/1-1/1-3/3	2,46
H9	1/1-1/1-1/3-3/3	3,57
H2	1/1-1/1-1/1-1/3	3,74
H72	1/4-1/2-1/1-3/3	3,82
H58	1/4-1/1-1/2-3/3	3,99
H4	1/1-1/1-1/2-3/3	8,07
H26	1/1-1/2-1/1-3/3	8,07
H55	1/4-1/1-1/1-1/3	8,41
H3	1/1-1/1-1/1-3/3	20,87



APOE Pharmacogenomics

APOE-Related Therapeutic Response to a Multifactorial Treatment in patients with Alzheimer's Disease




	APOE-2/3	APOE-3/3	APOE-3/4	APOE-4/4	Total
Minimum value	21,9	23,1	19,55	18,26	22,13
Maximum value	23,36	23,79	22,37	21,56	22,78
Average	22,53	23,39	20,86	19,8	22,55
Standard deviation	0,65	0,22	0,89	1,2	0,2
Correlation coefficient	-0,52	0,37	-0,24	-0,84	-0,19
R-squared	0,27	0,14	0,05	0,72	0,03
a Coefficient	23,23	23,21	21,31	21,89	22,63
b Coefficient	-0,2	0,05	-0,12	-0,59	-0,02
N	52	379	138	26	595
Females	30	220	83	18	351
Males	22	159	55	8	244
Age	64.36±11,47	65,55±10,60	68,63±9,87	65,88±9,26	66,23±10,58

R. Cacabelos, Expert Rev Mol Diag (2009)

CYP2D6-Related Therapeutic Response in Alzheimer's Disease

Cognitive Performance in Extensive (EM), Intermediate (IM), Poor (PM) and Ultra-rapid Metabolizers (UM)




	EM-0	EM-1	EM-3	EM-6	EM-9	EM-12	IM-0	IM-1	IM-3	IM-6	IM-9	IM-12	PM-0	PM-1	PM-3	PM-6	PM-9	PM-12	UM-0	UM-1	UM-3	UM-6	UM-9	UM-12
SD	9,02	7,46	6,99	5,17	8,09	5,81	6,28	5,58	6,2	6,48	6,39	5,07	6,72	6,52	6,11	5,39	5,52	5,86	6,76	5,67	4,62	5,68	4,99	7,75
X	21,58	21,57	21,53	21,54	22,66	23,78	21,4	21,67	22,2	22,1	22,5	22,71	20,74	20,65	20,24	19,04	18,57	18,07	22,65	23,02	22,49	21,73	21,34	21,28

Cacabelos et al (2007)

Interaction of CYP2D6 and APOE in the Pharmacogenetics of Alzheimer's Disease


Influence of APOE Genotypes on CYP2D6-Related Extensive (EM), Intermediate (IM) and Poor Metabolizers (PM)



Cacabelos (2007)

APOE-TOMM40 Region


1. Structural features of the APOE-TOMM40 region
2. APOE-related response to treatment
3. TOMM40-related response to treatment
4. APOE-TOMM40-related influence on therapeutic outcome



euroespes
PERSONALIZED MEDICINE
EUROESPES BIOMEDICAL RESEARCH CENTER
Institute of Medical Science and Genomic Medicine
rcacabelos@euroespes.com
www.euroespes.com

APOE-TOMM40 Haplotype

19q13.32



Alleles

TOMM40	APOE
Short (S): <19 poly T repeats	APOEε2
Large (L): 20-29	APOEε3
Very Large (VL): >30	APOEε4

Genotypes

rs10524523

TOMM40	APOE
S/S	ε2/ε2
S/L	ε2/ε3
S/VL	ε2/ε4
L/L	ε3/ε3
L/VL	ε3/ε4
VL/VL	ε4/ε4


Translocase of Outer Mitochondrial Membrane 40 homolog — Apolipoprotein E

Chair of Genomic Medicine
Camilo José Cela University

CAMILO JOSÉ CELA UNIVERSITY

APOE-TOMM40 Haplotype

19q13.32



Alleles

Translocase of Outer Mitochondrial Membrane 40 homolog	Apolipoprotein E
Short (S): <19	APOEε2
Large (L): 20-29	APOEε3
Very Large (VL): >30	APOEε4


Genotypes


rs10524523


S/S: 18.37%	ε2/ε2: 0%
S/L: 7.83%	ε2/ε3: 8.26%
S/VL: 38.80%	ε2/ε4: 1.96%
L/L: 1.52%	ε3/ε3: 51.52%
L/VL: 7.17%	ε3/ε4: 33.04%
VL/VL: 26.31%	ε4/ε4: 5.22%

Chair of Genomic Medicine
Camilo José Cela University


CAMILO JOSÉ CELA UNIVERSITY



Number of Females
Number of Males
Age at Onset (Years)
20 to 25,3333
25,3333 to 30,6667
30,6667 to 36
36 to 41,3333
41,3333 to 46,6667
46,6667 to 52
52 to 57,3333
57,3333 to 62,6667
62,6667 to 68
68 to 73,3333
73,3333 to 78,6667
78,6667 to 84
84 to 89,3333
89,3333 to 94,6667
94,6667 to 100
0%
1%
2%
5%
7%
12%
10%
18%
17%
16%
27%
23%
18%
17%
13%
4%
5%
2%








Chair of Genomic Medicine
Camilo José Cela University


Age-Related PolyT1/T2
PolyT1 (Red)
PolyT2 (Green)
Age-related trend (Blue)
N=1077
30
35
Linear Trend
7 Period Standard Deviation
TOMM40-PolyT1/T2 (repeats)
80
70
60
50
40
30
20
10
0
38
62
67
72
76
82
Age at Onset (Years)










Chair of Genomic Medicine
Camilo José Cela University


APOE-TOMM40 Association



Chair of Genomic Medicine
Camilo José Cela University


Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135


TOMM40-APOE Association





Chair of Genomic Medicine
Camilo José Cela University


Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135













Chair of Genomic Medicine
Camilo José Cela University


APOE-TOMM40 Haplotype-Related Pharmacogenetics



Chair of Genomic Medicine
Camilo José Cela University




Therapeutic response to a multifactorial treatment in patients with Alzheimer's disease




Chair of Genomic Medicine
Camilo José Cela University

Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135


Therapeutic response to a multifactorial treatment in females with Alzheimer's disease



Therapeutic response to a multifactorial treatment in males with Alzheimer's disease











Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135

Chair of Genomic Medicine
Camilo José Cela University










Chair of Genomic Medicine
Camilo José Cela University


Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135



Chair of Genomic Medicine
Camilo José Cela University

Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135


APOE-Related Response Ra



Chair of Genomic Medicine
Camilo José Cela University

Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135


TOMM40 Poly T-S/S



Chair of Genomic Medicine
Camilo José Cela University

Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135


TOMM40 Poly T-S/L



Chair of Genomic Medicine
Camilo José Cela University

Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135


TOMM40 Poly T-S/VL



Chair of Genomic Medicine
Camilo José Cela University

Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135


TOMM40 Poly T-L/L



Chair of Genomic Medicine
Camilo José Cela University

Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135


TOMM40 Poly T-L/VL



Chair of Genomic Medicine
Camilo José Cela University

Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135


TOMM40 Poly T-VL/VL



Chair of Genomic Medicine
Camilo José Cela University


Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135


TOMM40-Related Response



Chair of Genomic Medicine
Camilo José Cela University

Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135





S/S Coefficients:
b[0] 21,7661904762
b[1] -0,0271428571
r ² 0,0119968894

S/L Coefficients:
b[0] 19,659047619
b[1] -0,2282857143
r ² 0,3416140848

S/VL Coefficients:
b[0] 20,3595238095
b[1] -0,0351428571
r ² 0,0129660287

L/L Coefficients:
b[0] 19,7852380952
b[1] -0,5574285714
r ² 0,5651874665

L/VL Coefficients:
b[0] 18,2738095238
b[1] -0,1668571429
r ² 0,1902817865

VL/VL Coefficients:
b[0] 20,2771428571
b[1] -0,1268571429
r ² 0,2899741116

Chair of Genomic Medicine
Camilo José Cela University

Cacabelos R, Goldgaber D, Vostrov A, Matsuki H, Torrellas C, et al. (2014) APOE-TOMM40 in the Pharmacogenomics of Dementia. J Pharmacogenomics Pharmacoproteomics 5: 135. doi:10.4172/2153-0645.1000135

Conclusions

- A multifactorial treatment seems to be useful for patients with dementia in approximately 50% of the cases, stabilizing or improving cognitive deterioration for a transient period of time (<12 months).
- APOE-4 carriers are the worst responders and APOE-3 carriers are the best responders to conventional treatments.
- TOMM40 poly T-S/S carriers are the best responders, VL/VL and S/VL carriers are intermediate responders, and L/L carriers are the worst responders to treatment.

Conclusions

- Patients harboring a large (L) number of poly T repeats in intron 6 of the TOMM40 gene in haplotypes associated with APOE-4 are the worst responders to treatment.
- Patients with short (S) TOMM40 poly T variants (S/S genotype) and to a lesser extent S/VL and VL/VL carriers, in haplotypes with APOE-3 are the best responders to treatment.
- In 100% of the cases, the L/L genotype is exclusively associated with the APOE-4/4 genotype, and this haplotype (4/4-L/L) is probably responsible for an early onset of the disease, a faster cognitive decline, and a poor response to different treatments.

Chair of Genomic Medicine
Camilo José Cela University

euroespes

EUROESPES BIOMEDICAL RESEARCH CENTER
Institute of Medical Science and Genomic Medicine



/ PERSONALIZED MEDICINE
MEDICINA PERSONALIZADA /

T. (+34) 981 780 505
F. (+34) 981 780 511

info@euroespes.com
www.euroespes.com

Santa Marta de Babío s/n
15165 Bergondo · A Coruña, Spain